Astellas Pharma US, Inc announced the results of a pivotal phase 3 clinical trial for mirabegron, the first of a new class of compounds under development for the treatment of overactive bladder (OAB). Patients treated with mirabegron showed significant improvements in key OAB symptoms – urinary incontinence and frequency of micturition compared with placebo. These results were also associated with statistically significant improvements in patient reported outcomes.

Mirabegron is a potent and selective beta-3 adrenoceptor agonist. It activates beta-3 adrenoceptor on the detrusor muscle of the bladder to facilitate filling of the bladder and storage of urine.

For more information call (800) 727-7003 begin_of_the_skype_highlighting              (800) 727-7003      end_of_the_skype_highlighting or visit